Ticker Details
Corcept Therapeutics Incorporated Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.
IPO Date:	April 14, 2004
Sector:	Healthcare
Industry:	Pharma
Market Cap:	$4.49B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.31 | 2.78%
Avg Daily Range (30 D):	$0.92 | 2.57%
Avg Daily Range (90 D):	$1.31 | 2.80%

Institutional Daily Volume
Avg Daily Volume:	.51M
Avg Daily Volume (30 D):	1.42M
Avg Daily Volume (90 D):	1.71M

Trade Size
Avg Trade Size (Sh.):	97
Avg Trade Size (Sh.) (30 D):	55
Avg Trade Size (Sh.) (90 D):	60

Institutional Trades
Total Institutional Trades:	4,804
Avg Institutional Trade:	$2.93M
Avg Institutional Trade (30 D):	$3.95M
Avg Institutional Trade (90 D):	$4.07M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.24M
Avg Closing Trade (30 D):	$8.73M
Avg Closing Trade (90 D):	$10.89M
Avg Closing Volume:	143.62K

News

Apr 10, 2026 @ 5:56 PM INVESTOR DEADLINE: Corcept Therapeutics (CORT) Inv... Source: Hagens Berman

Apr 10, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Corcept Th... Source: Bronstein, Gewirtz & Grossman Llc

Apr 9, 2026 @ 12:00 PM Lead Plaintiff Deadlines in Shareholder Class Acti... Source: Holzer & Holzer, Llc

Apr 7, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Corcept Th... Source: Bronstein, Gewirtz & Grossman Llc

Apr 6, 2026 @ 3:17 AM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages C... Source: Rosen Law Firm

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$1	$.19	$.33
Diluted EPS	$.87	$.16	$.29
Revenue	$741.17M	$207.64M	$194.43M
Gross Profit	$727.78M	$203.04M	$191M
Net Income / Loss	$106.11M	$19.67M	$35.15M
Operating Income / Loss	$65.57M	$10.22M	$26.68M
Cost of Revenue	$13.39M	$4.6M	$3.43M
Net Cash Flow	$-12.15M	$22.39M	$12.93M
PE Ratio	48.44